Press Releases

Compugen to Host Q&A Conference Call on Wednesday, May 5, 2010 at 10:00 AM EDT

May 03, 2010
Q&A follows Q1 Corporate Presentation webcast and
conference call held on April 27, 2010


Tel Aviv, Israel, May 3, 2010 --- Compugen Ltd. (NASDAQ: CGEN) announced today that the Company will host a live Q&A conference call on Wednesday, May 5, 2010 at 10:00 AMEDT.The Q&A conference call is intended as a follow-up to the Q1 2010 conference call and webcast which took place on April 27, 2010.

During the Q1 2010 conference call, Compugen's chairman, Martin Gerstel, provided a company overview and outlook, including a slide presentation which was, and remains, posted on the Company's website, www.cgen.com, under the heading "Investors" and subheading "Financial Reports". However, following the slide presentation, the intended Q&A session was not possible due to technical difficulties.

The conference call, scheduled for Wednesday, May 5, 2010, will not involve any presentation by management and will be solely a Q&A session. To access the conference call please dial (toll free) 1-888-407-2553from the US, or +972-3-918-0644 internationally.

About Compugen
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen’s growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) “discovery on demand” agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN), to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com.

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as“may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.

Company contact:
Marjie Hadad
Global Media Liaison
Compugen Ltd.
Email: marjie@cgen.com
Tel: +972-54-536-5220

Dec 07, 2016

CGEN R&D Day 2016

NYC
MORE EVENTS
Banner